S-1/A: Apimeds Pharmaceuticals US, Inc. Files Amendment for Initial Public Offering

Apimeds Pharmaceuticals US, Inc. has filed an amendment to its registration statement for an initial public offering of its common stock, aiming to raise capital for clinical trials and operations.

Summary

• Apimeds Pharmaceuticals US, Inc., a clinical-stage biopharmaceutical company, is seeking to go public through an initial public offering (IPO).
• The company is developing Apitox, a bee venom-based treatment for osteoarthritis (OA) and potentially multiple sclerosis (MS).
• The IPO aims to raise funds for a Phase III trial in knee OA and early studies in MS.
• The company anticipates the initial public offering price of its shares will be between $3.00 and $4.00.
• Inscobee Inc., a South Korean corporation, will hold a majority of the voting power post-IPO.
• The company has a license agreement with Apimeds Korea for the rights to Apitox in the United States.
• The company has incurred net losses since inception and anticipates that it will continue to incur substantial net losses for the foreseeable future.
• The company has identified material weaknesses in its internal control over financial reporting.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there's potential in the technology and market, the company faces significant financial and regulatory hurdles, along with a dependence on a related party. The going concern warning and material weaknesses in internal controls are concerning.

Positives

• Apitox has shown therapeutic effects in a Phase III trial in South Korea for OA.
• A post-marketing safety study in South Korea showed no serious adverse events with Apitoxin.
• The company has a sublicensable, royalty-bearing license to utilize all prior clinical development data associated with Apitoxin.
• The company intends to initiate early prosecution of appropriate MS patient populations through non-registered corporate sponsorship studies.
• The company believes that naturalized bee venom can provide an additive treatment for OA and potentially MS.
• The FDA provides 12-year market exclusivity at the time of approval of a BLA, with the potential for a six-month extension upon approval for pediatric use.

Negatives

• The company has incurred significant net losses since inception and anticipates that it will continue to incur substantial net losses for the foreseeable future.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is substantially dependent on its relationships with Apimeds Korea.
• The company is dependent on the clinical success of Apitox in the treatment of symptoms of knee OA and MS in the United States.
• The company faces significant competition in the biopharmaceutical market.
• The company relies on trade secrets and other forms of non-patent intellectual property protection, which are difficult to protect.
• The company has limited experience designing and implementing clinical trials, and has never conducted pivotal clinical trials.

Risks

• Clinical development has inherent risk, and Apitox has limited patient exposure.
• The company may never achieve or maintain profitability.
• The company may require substantial additional funding to finance operations.
• The company's independent auditor included a going concern explanatory paragraph.
• The company's business is substantially dependent on its relationships with Apimeds Korea.
• The company faces significant competition, and competitors may develop more effective or less expensive products.
• The company's product candidate may cause undesirable side effects.
• The company relies on trade secrets and other forms of non-patent intellectual property protection, which are difficult to protect.
• The company is reliant on a single key supplier for bee venom.
• The company has limited experience designing and implementing clinical trials, and has never conducted pivotal clinical trials.

Future Outlook

The company intends to use the net proceeds from the IPO to fund a Phase III clinical trial in knee OA, initiate at least one non-registered company sponsored trial in MS, and for manufacturing costs and general corporate purposes. The company expects to finance its cash needs through public or private equity or debt financings, third-party funding, and strategic alliances.

Management Comments

• The advancement of Apitox as a candidate and Apimeds as a company, will be dictated by the clinical data and the regulatory agencies interpretation of such data in regard to effectiveness, safety and potential benefit beyond existing treatment options.
• Our approach with Apitox centers around this concept effectively treating certain symptoms of the patients disease, thus improving their overall quality of life.

Industry Context

The OA therapeutics market is expected to reach $20.24 billion by 2032, and the MS market is expected to reach $24.4 billion by 2030, indicating a significant market opportunity for Apitox.

Comparison to Industry Standards

• The document mentions Precedence Research estimates for the OA therapeutics market size in the United States, which was $8.28 billion in 2022 and is expected to reach $20.24 billion by 2032, expanding at a CAGR of 9.4% from 2023 to 2032. This indicates a growing market for OA treatments.
• The document also cites Pharmaceutical Technology estimates for the MS market size in the United States, which was $10.73 billion in 2022 and is expected to reach $24.4 billion by 2030, expanding at a CAGR of 10.32%. This shows a significant market for MS treatments.
• The document notes that Apitox is a purified, pharmaceutical grade bee venom, which is classified by the FDA as an active pharmaceutical ingredient (API). This is a unique approach compared to traditional pharmaceutical treatments for OA and MS.
• The document mentions that Apitoxin, the South Korean version of Apitox, has been approved by the Korean Ministry of Food and Drug Safety (MFDA) to treat pain and mobility in patients with OA since 2003. This provides a benchmark for the potential efficacy and safety of Apitox.
• The document states that Apimeds Korea successfully completed Phase I, Phase II, and Phase III trials in South Korea in OA in 2003. This is a positive sign for the potential of Apitox to succeed in clinical trials in the United States.
• The document also mentions that Apimeds Korea completed a Phase III trial in the United States in 2018, which showed therapeutic effect but did not meet the FDA's standards for approval. This highlights the challenges of obtaining FDA approval and the need for further clinical trials.
• The document notes that the company intends to pursue a second Phase III trial to meet agreed upon FDA standards. This is a common step in the drug development process and is necessary to obtain FDA approval.
• The document mentions that the FDA provides 12-year market exclusivity at the time of approval of a BLA, with the potential for a six-month extension upon approval for pediatric use. This is a standard regulatory protection for new biologics.

Related Party Transactions

• The company has a license agreement with Apimeds Korea for the rights to Apitox in the United States.
• The company has entered into a promissory note agreement with Inscobee Inc., one of its shareholders.
• The company has entered into a convertible note agreement with Apimeds Korea, one of its shareholders.
• The company has entered into a business development agreement with Murdock Capital Partners Corp.

Stakeholder Impact

• Shareholders will be subject to dilution from the IPO and potential future capital raises.
• Employees may benefit from the company's growth and potential success.
• Patients with OA and MS may benefit from the development of Apitox.
• Suppliers may benefit from increased demand for bee venom.
• Creditors may be impacted by the company's financial performance and ability to repay debt.

Next Steps

• The company intends to conduct a Phase III trial in knee OA.
• The company intends to initiate early prosecution of appropriate MS patient populations through non-registered corporate sponsorship studies.
• The company intends to submit a Biologics License Application (BLA) for Apitox with the Centers for Biologics and Research, in consultation with the FDA.

Key Dates

Keywords

Apitox, bee venom, osteoarthritis, multiple sclerosis, clinical trials, biopharmaceutical, IPO, FDA, Inscobee, Apitoxin